Provided by Integrity Continuing Education, Inc.
This activity is supported by independent educational grants from Biogen and EMD Serono, Inc.
Although the multifactorial causes of multiple sclerosis (MS) are not known, an improved understanding of the neuroimmunologic pathogenesis has led to the development of a wide variety of disease-modifying treatments (DMTs). While there is no cure for MS, these treatments can reduce disease activity and delay MS progression and disability.
However, having more DMT options than ever, and more still in clinical development, further complicates treating an already complex condition. With a wide variety of mechanisms of action (MOAs), selecting the optimal DMT is a formidable challenge with the opportunity to improve short-and long-term outcomes. Yet, using a treatment that is unsuitable to the patient’s individual disease activity, prognosis, and preferences is likely to lead to intolerable adverse events (AEs) and nonadherence. Given an MS patient’s immunosuppressed status and increased risk of infection. Adherence issues are further compounded during the pandemic as a result of stay-at-home orders.
Personalized treatment incorporates patient preferences for selecting, starting, switching, and stopping therapies as the patient’s circumstances change, as the disease progresses, and as the patient ages. Parsing the therapeutic alternatives can yield the most benefit when an interdisciplinary shared decision-making (SDM) approach is used.MS is a therapeutic area that is rapidly evolving and neurology clinicians need to remain updated on emerging therapies,
Through this initiative, participants will gain the knowledge and competence to develop early, aggressive plans that balance the benefits and risks of MS treatment options in order to optimize patient management through SDM.
Aaron Boster, MD
Founder and President
The Boster Center for Multiple Sclerosis
Barry A. Singer, MD
Director, The MS Center for Innovations in Care
St. Louis, Missouri
This program is intended for MS specialists, neurologists, internists, nurse practitioners, and physician assistants who are involved in the care of patients with MS.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:
Your certificate will be sent to you within four weeks of receipt of the completed evaluation.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme, Novartis
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme
Barry A. Singer, MD
Consulting and/or Speaking Fees: AbbVie, Alexion, Bayer, Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Janssen, Genentech, Greenwich Biosciences, Novartis, Roche, Sanofi Genzyme, Teva, TG Therapeutics
Institution Research Grants: AbbVie, Alkermes, Bayer, Biogen, MedImmune, Novartis, Roche, Sanofi Genzyme
Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
On the day of the program, you may access the event by going to any of the following links:
There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 0.75 AMA PRA Category 1 CME credit(s)™. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within 30 days of the activity and submission of a completed activity evaluation form.